Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How

Nicotine Tob Res. 2018 Mar 6;20(4):414-424. doi: 10.1093/ntr/ntx097.

Abstract

This article outlines a framework for the consistent integration of biological data/samples into smoking cessation pharmacotherapy trials, aligned with the objectives of the recently unveiled Precision Medicine Initiative. Our goal is to encourage and provide support for treatment researchers to consider biosample collection and genotyping their existing samples as well as integrating genetic analyses into their study design in order to realize precision medicine in treatment of nicotine dependence.

Publication types

  • Meta-Analysis
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Clinical Trials as Topic / methods
  • Genomics / methods*
  • Humans
  • Precision Medicine / methods*
  • Precision Medicine / psychology
  • Smoking / genetics*
  • Smoking / psychology
  • Smoking / therapy*
  • Smoking Cessation / methods*
  • Smoking Cessation / psychology
  • Tobacco Use Cessation Devices
  • Tobacco Use Disorder / genetics
  • Tobacco Use Disorder / psychology
  • Tobacco Use Disorder / therapy